Cochrane · systematic review · CD013004
Ivabradine as adjuvant treatment for chronic heart failure
Benstoem, C, Kalvelage, C, Breuer, T, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
13
No studies
15
Included studies
NR
No studies 15 · 53.6%Ungraded 0 · 0%Very low 0 · 0%Low 10 · 35.7%Moderate 2 · 7.1%High 1 · 3.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)
Population: adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality from cardiovascular causes ( Usual care with ivabradine vs placebo, usual care, or no treatment | RR 0.99 [0.88, 1.11] | 3 studies · 17676 participants | Moderate Downgraded: indirectness |
Quality of life Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 2 studies · 2102 participants | Low Downgraded: risk of bias |
Time to first hospitalisation for heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Number of days spent in hospital due to heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Rate of serious adverse events Usual care with ivabradine vs placebo, usual care, or no treatment | RR 0.96 [0.92, 1] | 2 studies · 17399 participants | Moderate Downgraded: indirectness |
Exercise capacity Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 158 participants | Low Downgraded: risk of bias, imprecision |
Economic costs Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 6558 participants | High |
Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (< 6 months) with ivabradine)
Population: adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality from cardiovascular causes ( Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Quality of life Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
Time to first hospitalisation for heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Number of days spent in hospital due to heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Rate of serious adverse events Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 2 studies · 270 participants | Low Downgraded: imprecision, publication bias |
Exercise capacity Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 3 studies · 305 participants | Low Downgraded: risk of bias, imprecision |
Economic costs Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)
Population: adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality from cardiovascular causes Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 178 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 179 participants | Low Downgraded: risk of bias, imprecision |
Time to first hospitalisation for heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Number of days spent in hospital due to heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Rate of serious adverse events Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 179 participants | Low Downgraded: risk of bias, imprecision |
Exercise capacity Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 1 study · 179 participants | Low Downgraded: risk of bias, imprecision |
Economic costs Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (< 6 months) with ivabradine)
Population: adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality from cardiovascular causes ( Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Quality of life Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Time to first hospitalisation for heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Number of days spent in hospital due to heart failure during Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Rate of serious adverse events Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |
Exercise capacity Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | 2 studies · 171 participants | Low Downgraded: imprecision, inconsistency |
Economic costs Usual care with ivabradine vs placebo, usual care, or no treatment | no estimate extracted | NR | No studies |